Eisai Co Ltd announces new partnership with Esteve to promote anti-epilepsy drug Zonegran (Zonisamide) in Spain


Monday, 9 Dec 2013 07:02pm EST 

Eisai Co Ltd:Says that it has selected Esteve, a Spanish pharmaceutical company with a comprehensive neurology franchise, to become its epilepsy partner in Spain to promote Zonegran (zonisamide).Says Zonisamide, an anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AED, is indicated as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;.Says and as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents and children aged six years and above. 

Company Quote

4372.0
31.5 +0.73%
9:30pm EDT